Teva submits NDA for ecopipam in pediatric Tourette syndrome, introducing a D1 receptor antagonist mechanism after a decade without...

Nature Medicine just made the case for large-scale RCTs of live-attenuated shingles vaccination for dementia prevention. Acting Commissioner Diamantas,...

Zabopegdutide demonstrates 81.8% fibrosis response in Phase 2 MASH trial, with AI pathology analysis confirming 41% relative reduction in...

Elicio reports three complete responses with ELI-002 7P in metastatic pancreatic cancer patients receiving subsequent checkpoint inhibitor therapy.

uniQure plans BLA submission for AMT-130 gene therapy in Huntington's disease, targeting Q3 2026 based on 36-month efficacy data.

Olorofim meets non-inferiority goal in Phase 3 invasive aspergillosis trial, showing 23.8% mortality versus 24.3% for AmBisome with significantly...

FDA approves oral carbapenem Utebzi for complicated UTIs, offering an IV-to-oral step-down option for hospitalized patients with resistant infections.

FDA accepts Lunsumio and Polivy combo for relapsed refractory B-cell lymphoma, with phase III data showing 11.5-month median PFS...

The OCTOPUS progressive MS platform trial has enrolled 700+ participants across dynamic arms. Here's what sites need to know...

A Nature Medicine randomized trial shows adaptive DBS cuts gait variability in Parkinson's. The real story is what its...